Cost-effectiveness of acalabrutinib regimens in treatment-naïve chronic lymphocytic leukemia in the United States.

Tahla MunirVictoria GenovezVictor GenestierKellie RyanBengt LiljasPriyanka Gaitonde

Published in: Expert review of pharmacoeconomics & outcomes research (2023)

Although the analysis is limited by uncertainty in postprogression survival outcomes, acalabrutinib monotherapy is likely cost effective vs chlorambucil + obinutuzumab in treatment-naïve CLL in the US Medicare setting.

Keyphrases

chronic lymphocytic leukemia
combination therapy
clinical trial
open label
randomized controlled trial
study protocol
replacement therapy